Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV.

Autor:	Mazzitelli M; Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy., Agostini E; Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy., Vania E; Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy., Presa N; Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy., Sasset L; Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy., Leoni D; Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy., Gardin S; Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy., Scaglione V; Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy., Cattelan A; Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy.
Jazyk:	angličtina
Zdroj:	HIV research & clinical practice [HIV Res Clin Pract] 2024 Dec; Vol. 25 (1), pp. 2351258. Date of Electronic Publication: 2024 May 10.
Abstrakt:	Background: Recently, injectable cabotegravir/rilpivirine (ICAB/RPV) became available for HIV treatment. However, there are no real-life data on the impact of switching to ICAB/RPV on sleep disturbances (SD). Therefore, we aimed at assessing and investigating this aspect in our cohort. Methods: A SD multidimensional assessment (Epworth Sleepiness scale, Insomnia severity Index, Berlin Questionnaire, and Pittsburg Sleep Quality Index, PSQI) was performed to all people who consented before starting ICAB/RPV and 12 wk after the switch. Demographics, life-style habits, laboratory, and clinical data were collected from medical health records. Results: To June 2023, 46 people were included, 76.1% males, with a median age of 48.5 (IQR: 41-57), 50% had multimorbidity, 13% was on polypharmacy. Median age with HIV and CD4 + T cell count nadir were 10 (5-19.5) years and 360 (205-500) cell/mm 3 , respectively. The reason to start a long-acting strategy was person's choice in all cases. Baseline antiretroviral regimens were mostly: tenofovir alafenamide/emtricitabine/rilpivirine (39.1%) and dolutegravir/lamivudine (32.6%). No significant changes were observed in any of the scores for each questionnaire, but for a worsening PSQI. 37% people reported a subjectively improved sleep quality, even if statistically significant changes were not observed in almost all the sleep parameters. Conclusions: To the best of our knowledge, this is the first study exploring impact of switching to ICAB/RPV on SD. Despite integrase inhibitor have been associated with SD, we did not observed a negative impact on sleep quality after the switch to ICAB/RPV. More studies and with larger number of people are necessary to confirm our results.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu